Clinical Trial Search

Primary: Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -9.6; -10.5; -7.4 Rating score — p=0.006

Primary: Percentage of Seroprotected Subjects Against Anti-Hepatitis B (HBs) Antigen — 100; 96 Percentage of subjects

Primary: Median Change in Apnea-hypopnea Index (AHI) — 3.8; 8.0 events per hour of sleep — p=.590

Primary: Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period — 36.7; 63.2; 49.8; 26.7 Seconds — p=0.321

Primary: Number of Participants With a Confirmed Response [Complete Response (CR) and Partial Response (PR)] on 2 Consecutive Evaluations at Least 4 Weeks Apart — 0 participants

Primary: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) — -0.031; 0.129; 0.093; 0.207 Liters — p=<0.001

Primary: Change From Baseline in Cortical Silent Period (CSP) Will be Determined Using Transcranial Magnetic Stimulation (TMS) of the Motor Cortex. — 0.001; 0.006 seconds

Primary: Change From Baseline in Weighted Mean Pulse Rate Over 0 to 6 Hours Post-dose at Day 28 — 1.4; 0.9 Beats per minutes (bpm)

Primary: Geometric Mean Titers Against the Influenza Virus Antigens Following Vaccination With Either a Quadrivalent Influenza Vaccine or a Trivalent Influenza Vaccine…

Primary: Number of Participants Showing Reduction or Elimination of Skin Blistering — 0; 8 participants

Primary: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) — 0.121; 0.211; 0.209; 0.121 Liters — p=<0.001

Primary: Transformed Descriptor Differential Scale-Pain Intensity Scores Adjusted for Time — 0.6683; 0.6988 units on a scale — p=0.4237

Primary: HPV Prevalence — 61 participants

Primary: Number of Seroconverted Subjects Against the A/Indonesia/5/2005 (H5N1) Strain of Influenza Disease. — 63; 64; 53; 54 Subjects

Primary: Progression Free Survival (PFS) During the First-line Treatment Phase — 6.9; 5.5 Months — p=0.051